Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2−) advanced breast cancer patients: New insights beyond clinical trials. The EVA studyMarina Elena Cazzaniga, Martina Dester, Mario Airoldi et al.|The Breast|2017Cited by 23
Safety and efficacy of eribulin plus trastuzumab in pretreated HER2-positive advanced breast cancer (ABC) patients. An Italian multicenter experienceE.S. Lutrino, Saverio Cinieri, A. Quaranta et al.|Annals of Oncology|2016Cited by 1
Abstract P4-13-15: Dose intensity and efficacy of the combination of everolimus and exemestane (EVE/EXE) in a real world population of hormone receptor positive advanced breast cancer: A multicenter Italian experienceR. Forcignanò, Mariangela Ciccarese, Luciana Petrucelli et al.|Cancer Research|2016Cited by 0
Safety of Eribulin plus Trastuzumab in pre-treated HER2-positive advanced breast cancer (ABC) patients: results from an Italian observational studyLaura Orlando, Saverio Cinieri, E.S. Lutrino et al.|Annals of Oncology|2016Cited by 0